[HTML][HTML] Effectiveness of the BNT162b2 Covid-19 Vaccine against the B. 1.1. 7 and B. 1.351 Variants
LJ Abu-Raddad, H Chemaitelly… - New England Journal of …, 2021 - Mass Medical Soc
New England Journal of Medicine, 2021•Mass Medical Soc
Efficacy of the BNT162b2 mRNA Vaccine in Qatar As of March 31, 2021, more than 265,000
people in Qatar had received both doses of the BNT162b2 vaccine. Viral sequencing
indicated that 50.0% of infections from February 23 to March 18 were caused by B. 1.351
and 44.5% by B. 1.1. 7. Vaccine effectiveness was 89.5% against the B. 1.1. 7 variant and
75.0% against the B. 1.351 variant. Effectiveness against severe, critical, or fatal disease
was 97.4%.
people in Qatar had received both doses of the BNT162b2 vaccine. Viral sequencing
indicated that 50.0% of infections from February 23 to March 18 were caused by B. 1.351
and 44.5% by B. 1.1. 7. Vaccine effectiveness was 89.5% against the B. 1.1. 7 variant and
75.0% against the B. 1.351 variant. Effectiveness against severe, critical, or fatal disease
was 97.4%.
Efficacy of the BNT162b2 mRNA Vaccine in Qatar
As of March 31, 2021, more than 265,000 people in Qatar had received both doses of the BNT162b2 vaccine. Viral sequencing indicated that 50.0% of infections from February 23 to March 18 were caused by B.1.351 and 44.5% by B.1.1.7. Vaccine effectiveness was 89.5% against the B.1.1.7 variant and 75.0% against the B.1.351 variant. Effectiveness against severe, critical, or fatal disease was 97.4%.
The New England Journal Of Medicine